Congress Reins In Drug Middlemen in Effort to Lower Prescription Prices

THE NEW YORK TIMES

The spending package passed by Congress on Tuesday includes an effort to drive down drug prices, by imposing new restrictions on some of the most controversial practices of the giant companies that oversee prescription benefits.

The legislation represents a significant political defeat for the companies, known as pharmacy benefit managers, or P.B.M.s, which for years had largely escaped public attention, regulation and oversight. And it represents a win for drugmakers, which have long lobbied to deflect blame for high drug prices toward the P.B.M.s.

In signing the overall package on Tuesday afternoon, President Trump singled out his efforts to reduce drug prices.

Read more here.